Each 20 ml vial of MyMust contains 100 mg of Bendamustine as lyophilized powder.
MyMust (Bendamustine Hydrochloride) Injection is indicated for the treatment of patients with indolent B-cell Non-Hodgkins lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab containing regimen. MyMust (Bendamustine hydrochloride) is also indicated for the treatment of patients with Chronic Lymphocytic Leukaemia (CLL). Efficacy relative to rst line therapies other than chlorambucil has not been established
The diluted solution of Bendamustine is stable at controlled room temperature (15-25Ã‚Â°C) for 3 hours and for 24 hours when it is stored at 2-8Â°C. Safe Handling and Disposal As with any other cytotoxic agent, appropriate care should be taken during preparation, administration and disposal of Bendamustine. Adverse Events associated with the use of Bendamustine in CLL may include, but are not limited to, the following: Neutropenia, Diarrhea, Thrombocytopenia, Fatigue, Anemia, Asthenia, Leukopenia, Pyrexia Lymphopenia Infections, Nausea, Hyperuricemia, Vomiting, Skin Rash
MyMust 100 mg for injection is supplied in 20 ml amber colour vials containing 100 mg of lyophilized, white to off-white powder of Bendamustine hydrochloride and a 20ml sterile water for injection IP, housed in a carton.
MyMust should be stored below 25°C, with excursions permitted up to 30Â°C. Retain the product in the original carton until the time of use to protect it from light